BLUE Quote, Trading Chart, bluebird bio Inc.
home / stock / blue / blue quote
$ Last:
Change Percent:
$ Open:
$ Previous Close:
$ High:
$ Low:
0 Volume:
01/01/1970 12:00:00 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-03-02 | 29.6 | 30.8 | 30.94 | 29.31 | 2,977,851 |
| 2021-03-01 | 31.39 | 30.08 | 32.0645 | 29.6 | 3,039,825 |
| 2021-02-26 | 28.24 | 31.1 | 31.1413 | 27.43 | 5,871,754 |
| 2021-02-25 | 25.93 | 28.12 | 28.35 | 25.6 | 8,275,057 |
| 2021-02-24 | 26.3 | 25.92 | 26.69 | 25.62 | 3,511,861 |
| 2021-02-23 | 25.94 | 25.62 | 26.45 | 24.24 | 4,421,675 |
| 2021-02-22 | 26.72 | 26.07 | 27.09 | 26.01 | 2,531,149 |
| 2021-02-19 | 27.3 | 26.68 | 27.3199 | 26.565 | 4,473,845 |
| 2021-02-18 | 28.1 | 26.95 | 28.23 | 26.85 | 4,438,602 |
| 2021-02-17 | 28.59 | 28.02 | 29.95 | 27.72 | 6,769,948 |
| 2021-02-16 | 33.5 | 28.44 | 34.36 | 26.11 | 17,970,004 |
| 2021-02-15 | 45.52 | 45.76 | 46.45 | 44.65 | 771,677 |
| 2021-02-12 | 45.52 | 45.76 | 46.45 | 44.65 | 763,983 |
| 2021-02-11 | 46.75 | 45.77 | 47.09 | 44.66 | 795,933 |
| 2021-02-10 | 46.81 | 46.52 | 47.19 | 45.52 | 742,137 |
| 2021-02-09 | 48.11 | 46.54 | 48.43 | 46.4 | 750,419 |
| 2021-02-08 | 48.11 | 47.89 | 48.92 | 47.3 | 1,017,426 |
| 2021-02-05 | 47.41 | 47.7 | 47.88 | 47.03 | 960,010 |
| 2021-02-04 | 46.73 | 47.28 | 47.42 | 45.9129 | 842,661 |
| 2021-02-03 | 46.74 | 46.45 | 47.86 | 46.42 | 783,025 |
News, Short Squeeze, Breakout and More Instantly...
-
Walmart (NYSE: WMT) shares slip on earnings. The Trade Desk (NASDAQ: TTD) surges on record revenue. Roku (NASDAQ: ROKU) rises on an unexpected profit. Fastly (NYSE: FSLY) falls on growth concerns. Shopify (NYSE: SHOP) slips. CVS Health (NYSE: CV...
-
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen 41 st Annual Health Care Conference, Wednesday, March 3, at 2:40 p.m. ET. To access the live webcast of bluebird bio’s presentation, please visit the ȁ...
-
First pivotal study of BCMA-directed CAR T cell therapy in triple-class exposed relapsed and refractory multiple myeloma Biologics License Application (BLA) for ide-cel was accepted by FDA for Priority Review, with a target action date of March 27, 2021 Results from ...